1. Repositório Institucional Unichristus
  2. Cursos de Graduação
  3. Odontologia
  4. Odontologia - Trabalhos de Conclusão de Curso - Campus PARQUE ECOLÓGICO
Please use this identifier to cite or link to this item: https://repositorio.unichristus.edu.br/jspui/handle/123456789/1725
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorSilva, Paulo Goberlânio Barros-
dc.contributor.authorAraújo, Clarice Lioba de-
dc.date.accessioned2024-08-19T18:53:13Z-
dc.date.available2024-08-19T18:53:13Z-
dc.date.issued2024-06-20-
dc.identifier.urihttps://repositorio.unichristus.edu.br/jspui/handle/123456789/1725-
dc.descriptionBAE, B. et al. Safety and long-term efficacy of forehead contouring with a polycaprolactone-based dermal filler. Dermatologic Surgery, Seoul, v. 42, n. 11, p. 1256-1260, 2016. BAUMANN, L. Dermal fillers. J Cosmet Dermatol., Miami, v. 3, n. 4, p. 249-250, 2004. BELJAARDS, R. C.; DE ROOS, K.P.; BRUINS, F.G. NewFill for skin augmentation: a new filler or failure?. Dermatologic surgery, Veghel, v. 31, n. 7, p. 772-777, 2005. BENTKOVER, S.H. The biology of facial fillers. Facial Plast Surg.,Worcester, v. 25, n. 2, p. 73-85, 2009. BORBA, A,; MATAYOSHI, S. Técnicas de rejuvenescimento facial: toxina botulínica e MD codes. 1. ed. Rio de Janeiro: Editora Buzz, 2018. BRAVO, B. S. F.; CARVALHO, R. M. Safety in immediate reconstitution of poly‐l‐lactic acid for facial biostimulation treatment. Journal of Cosmetic Dermatology, Rio de Janeiro, v. 20, n. 5, p. 1435-1438, 2021. CABRAL, L. R. B. et al. Effect of hyaluronic acid and poly-l-lactic acid dermal fillers on collagen synthesis: An in vitro and in vivo study. Clinical, Cosmetic and Investigational Dermatology, São Paulo, v. 13, p. 701, 2020. CHEN, S.I.; CHENG, S.X.; ZHUO, R.X. Self‐assembly strategy for the preparation of polymer‐based nanoparticles for drug and gene delivery. Macromolecular bioscience, Wuhan, v. 11, n. 5, p. 576-589, 2011. CHEN, S.Y.; LIN, J.Y.; LIN, C.Y. The back-and-forth method: A quick and simple technique for reconstitution of injectable poly-D, L-lactic acid. Archives of Aesthetic Plastic Surgery, Taiwan, v. 26, n. 2, p. 79-83, 2020a. CHEN, S.Y.; LIN, J.Y.; LIN, C.Y. Micro-Fisheyes of Carboxymethyl Cellulose: The Cause of Micro-Clumps in the Suspension of Injectable Poly-l-Lactic Acid. Aesthetic Surgery Journal, Taipei, v. 40, n. 6, p. NP409-NP411, 2020b. CHRISTEN, M.O.; VERCESI, F. Polycaprolactone: How a well-known and futuristic polymer has become an innovative collagen-stimulator in esthetics. Clinical, Cosmetic and Investigational Dermatology, Paris, v. 13, p. 31-48, 2020. DE LIMA, N.B.; SOARES, M.L. Utilização dos bioestimuladores de colágeno na harmonização orofacial. Clinical and Laboratorial Research in Dentistry, Recife, p. 1-18, 2020. DE MELO, F.; MARIJNISSEN-HOFSTÉ, J. Investigation of physical properties of a polycaprolactone dermal filler when mixed with lidocaine and lidocaine/epinephrine. Dermatology and Therapy, Dubai, v. 2, n. 1, p. 1-10, 2012. DE MELO, F. et al. Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone-based collagen stimulator (Ellansé®). Clinical, Cosmetic and Investigational Dermatology, Paris, v. 10, p. 431- 440, 2017. FITZGERALD, R.; VLEGGAAR, D. Facial volume restoration of the aging face with poly‐l‐lactic acid. Dermatologic therapy, Los Angels, v. 24, n. 1, p. 2-27, 2011. FLORES, I.C.; GONZÁLEZ, J. L.M. Materiales de relleno en dermatología. Dermat CMQ, Monterrey, n. 9, v.4, p. 275-283, 2011. GALADARI, H. et al. A randomized, prospective, blinded, split‐face, single‐center study comparing polycaprolactone to hyaluronic acid for treatment of nasolabial folds. Journal of cosmetic dermatology, Al Ain, v. 14, n. 1, p. 27-32, 2015. GOLDBERG, D. et al. Single‐arm study for the characterization of human tissue response to injectable poly‐L‐lactic acid. Dermatologic Surgery, New York, v. 39, n. 6, p. 915-922, 2013. GOLDMAN, M. P. Cosmetic use of poly-L-lactic acid: my technique for success and minimizing complications. Dermatologic surgery, San Diego, v. 37, n. 5, p. 688-693, 2011. GOODWIN, P. Collagen stimulation with a range of polycaprolactone dermal fillers. Journal of Aesthetic Nursing, [s. l.], v. 2S, p. 22-28, 2018. HADDAD, A. et al. Conceitos atuais no uso do ácido poli-l-láctico para rejuvenescimento facial: revisão e aspectos práticos. Surgical & Cosmetic Dermatology, São Paulo, v. 9, n. 1, p. 60-71, 2017. KEDE, M.P.V.; SABATOVICH, O. Dermatologia estética. 2. ed. rev.São Paulo: Atheneu, 2009. KIM, J.A.; ABEL, D.V. Neocollagenesis in human tissue injected with a polycaprolactone-based dermal filler. J Cosmet Laser Ther., [s. l.], v. 17, n. 2, p. 99-101, 2015. KIM, J.S. et al. Comparative study of rheological properties and preclinical data of porous polycaprolactone microsphere dermal fillers. Journal of Cosmetic Dermatology, Korea, v. 19, n. 3, p. 596-604, 2020. KWON, T.R. et al. Biostimulatory effects of polydioxanone, poly‐d, l lactic acid, and polycaprolactone fillers in mouse model. Journal of Cosmetic Dermatology, Korea, v. 18, n. 4, p. 1002-1008, 2019. LACOMBE, V. Sculptra: a stimulatory filler. Facial Plastic Surgery, Santa Rosa, v. 25, n. 02, p. 95-99, 2009. LAM, S. M.; AZIZZADEH, B.; GRAIVIER, M. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plastic and reconstructive surgery, [s. l.], v. 118, n. 3S, p. 55S-63S, 2006. LE LOUARN, C.; BATHIAU, D.; BUIS, J. Structural aging: the facial recurve concept. Aesthetic Plastic Surgery, Paris, v. 31, n. 3, p. 213-218, 2007. LEVY, P. M.; BOULLE, K.D.; RASPALDO, H. A split‐face comparison of a new hyaluronic acid facial filler containing pre‐incorporated lidocaine versus a standard hyaluronic acid facial filler in the treatment of naso‐labial folds. Journal of Cosmetic and Laser Therapy, Geneva, v. 11, n. 3, p. 169-173, 2009. LIN, S.L. Polycaprolactone facial volume restoration of a 46‐year‐old Asian women: a case report. Journal of Cosmetic Dermatology, New Taipei City, v. 17, n. 3, p. 328-332, 2018. MESQUITA, K. C. et al. Abatacept treatment impairs the cell migration and wound healing of oral ulcers in rats: Role of interleukin (IL)-1β,-6 and-10 and CD8/CD30 cells: Influence of abatacept treatment on oral wound healing: Experimental model on rats. Life sciences, Fortaleza, v. 243, 2020. NARINS, R. S. et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. Journal of the American Academy of Dermatology, New York, v. 62, n. 3, p. 448-462, 2010. QUAN, T. et al. Reduced expression of connective tissue growth factor (CTGF/CCN2) mediates collagen loss in chronologically aged human skin. Journal of Investigative Dermatology, Michigan, v. 130, n. 2, p. 415-424, 2010. RAYESS, H. M. et al. A cross-sectional analysis of adverse events and litigation for injectable fillers. JAMA facial plastic surgery, Detroit, v. 20, n. 3, p. 207-214, 2018. SCHIERLE, C. F.; CASAS, L. A. Nonsurgical rejuvenation of the aging face with injectable poly-L-lactic acid for restoration of soft tissue volume. Aesthetic surgery journal, Chicago, v. 31, n. 1, p. 95-109, 2011. SCULPTRA: suspensão. Responsável técnico: Thereana Rimerio. Hortolândia – Galderma, 2021. SHAW, R.B.; KAHN, D.M. Aging of the midface bony elements: a three-dimensional computed tomographic study. Plastic and reconstructive surgery, Stanford, v. 119, n. 2, p. 675-681, 2007. SMITH, L.; COCKERHAM, K. Hyaluronic acid dermal fillers: can adjunctive lidocaine improve patient satisfaction without decreasing efficacy or duration?. Patient preference and adherence, Los Altos, n. 5, p. 133-139, 2011. SUN, H. et al. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials, Tianjin, v. 27, n. 9, p. 1735-1740, 2006. TAGLE, J.M. et al. Clinical performance of a dermal filler containing natural glycolic Acid and a polylactic Acid polymer: results of a clinical trial in human immunodeficiency virus subjects with facial lipoatrophy. J Clin Aesthetic Dermatol, [s. l.], v. 3, n.2, p. 42-47, 2010. VARGAS, A.; DE AMORIM, N.G.; PINTAGUY, I. Complicações tardias dos preenchimentos permanentes. Revista Brasileira de Cirurgia Plástica, Rio de Janeiro, v. 24, n. 1, p. 71-81, 2009. VERHAEGEN, P.D.H.M. et al. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: an objective histopathological analysis. Wound repair and regeneration, Beverwijk, v. 17, n. 5, p. 649-656, 2009. WOODRUFF, M.A.; HUTMACHER, D.W. The return of a forgotten polymer—Polycaprolactone in the 21st century. Progress in Polymer Science, Australia, v. 35, p. 1217–1256. 2010. WORTSMAN, X.; QUEZADA, N. Ultrasound morphology of polycaprolactone filler. Journal of Ultrasound in Medicine, Santiago, v. 36, n. 12, p. 2611-2615, 2017.pt_BR
dc.description.abstractTem sido sugerido que o Ellansé, composto por microesferas de policaprolactona (PCL) em solução aquosa de gel de carboximetilcelulose (CMC), seja diluído como forma de aumentar seu rendimento e que o Sculptra®, um polímero sintético apresentado na forma de um pó liofilizado que após reconstituição gera uma matriz que estimula a colagênese, seja reconstituído em períodos menor que o indicado pelo fabricante. Dessa forma, o objetivo do presente trabalho é avaliar o percentual de indução de neocolagênese dos preenchedores Ellansè® e Sculptra® em diferentes formas de apresentação e reconstituição. Para isso, foram utilizado 270 camundongos da linhagem Swiss (Mus musculus) machos entre quatro e seis semanas em cujos subcutâneo do dorso foram aplicados 0,1 ml de solução salina contendo 5% de anestésico local subcutânea; 0,1 ml de Ellansé® sem nenhuma diluição ou diluído 1:1 (50%),1:2 (66%) e 1:4 (83%) ou Sculptra® reconstituído imediatamente antes da aplicação, 2h , 24h ou 72h antes da administração e foram eutanasiados após 15, 30 e 60 dias da administração do material em número de 10/grupo/dia. Foram removidos seus dorsos para análise histológica da quantidade de colágeno utilizando a coloração de Picrosirius Red e imunoexpressão para alfaactina de músculo liso. Teste ANOVA/Bonferroni foi utilizado (p<0,05, GraphPad Prism 5.0). Após 15 dias de administração não houve diferença significativa entre os grupos estudados (p=0,955). Após 30 dias da administração do Ellansé® 83% e 100% (p<0,001) e o grupo Sculptra 72h (p=0,016) apresentaram maior formação de colágeno que o grupo salina. Após 60 dias os grupos com Ellansé® 83% e 100% também apresentaram maior formação de colágeno que o grupo salina (p=0,012) bem como os grupos Sculptra 24h, 48h e 72h (p=0,025). Após 30 dias da administração os grupos Sculptra 24h e 72h apresentam maior imunoexpressão para α-AML (p=0,001), bem como após 60 dias da administração Ellansé® 100% (p=0,012) e Sculptra 24h e 72h (p<0,001). Dessa forma, a mistura da solução de lidocaína com o material de preenchimento inibe a necessidade de bloqueios nervosos ou infiltração local, diminuindo assim a dor relacionada ao tratamento e evitando a distorção tecidual que pode ser provocada pela injeção de anestésicos locais. Ademais, pode ter um impacto positivo no tratamento, melhorando a qualidade do atendimento e a satisfação do paciente. Dessa forma, com a finalidade de neocolagêse a diluição de Ellansé® ou reconstituição de Sculptra® em períodos inferiores às 24h são contraindicados.pt_BR
dc.language.isopt_BRpt_BR
dc.subjectdermal fillerspt_BR
dc.subjectcolágenopt_BR
dc.subjectpolicaprolactonapt_BR
dc.subjectácido poli-l-lácticopt_BR
dc.titlePOLICAPROLACTONA E ÁCIDO POLI-L-LÁTICO: É POSSÍVEL OTIMIZAR E REDUZIR CUSTOS DURANTE HARMONIZAÇÃO OROFACIAL COM INDUTORES DE COLÁGENO? UM ESTUDO IN VIVOpt_BR
dc.typeTCCpt_BR
dc.title.inglesPOLYCAPROLACTONE AND POLY-L-LACTIC ACID: IS IT POSSIBLE TO OPTIMIZE AND REDUCE COSTS DURING OROFACIAL HARMONIZATION WITH COLLAGEN INDUCERS? AN IN VIVO STUDYpt_BR
dc.description.resumo_abstractIt has been suggested that Ellansé®, composed of polycaprolactone (PCL) microspheres in an aqueous solution of carboxymethyl cellulose (CMC) gel, be diluted as a way of increasing its yield and that Sculptra®, a synthetic polymer presented in the form of a powder freeze-dried product that, after reconstitution, generates a matrix that stimulates collagengenesis, must be reconstituted in periods shorter than that indicated by the manufacturer. Therefore, the objective of the present work is to evaluate the percentage of neocollagenesis induction of Ellansé® and Sculptra® fillers in different forms of presentation and reconstitution. For this, 270 male Swiss mice (Mus musculus) aged between four and six weeks were used, to which 0.1 ml of saline solution containing 5% local anesthetic was applied subcutaneously; 0.1 ml of Ellansé® without any dilution or diluted 1:1 (50%), 1:2 (66%) and 1:4 (83%) or Sculptra® reconstituted immediately before application, 2h, 24h or 72h before administration and were euthanized after 15, 30 and 60 days of administration of the material in a number of 10/group/day. Their backs were removed for histological analysis of the amount of collagen using Picrosirius Red staining and immunoexpression for alpha-smooth muscle actin. ANOVA/Bonferroni test was used (p<0.05, GraphPad Prism 5.0). After 15 days of administration there was no significant difference between the groups studied (p=0.955). After 30 days of administration of Ellansé®, 83% and 100% (p<0.001) and the Sculptra 72h group (p=0.016) showed greater collagen formation than the saline group. After 60 days, the groups with Ellansé® 83% and 100% also showed greater collagen formation than the saline group (p=0.012) as well as the Sculptra 24h, 48h and 72h groups (p=0.025). After 30 days of administration, the Sculptra 24h and 72h groups showed higher immunoexpression for α-AML (p=0.001), as well as after 60 days of administration Ellansé® 100% (p=0.012) and Sculptra 24h and 72h (p<0.001). In this way, mixing the lidocaine solution with the filling material inhibits the need for nerve blocks or local infiltration, thus reducing treatment-related pain and avoiding tissue distortion that can be caused by the injection of local anesthetics. Furthermore, it can have a positive impact on treatment, improving the quality of care and patient satisfaction. Therefore, for the purpose of neocolagesis, dilution of Ellansé® or reconstitution of Sculptra® in periods of less than 24 hours are contraindicated.pt_BR
Appears in Collections:Odontologia - Trabalhos de Conclusão de Curso - Campus PARQUE ECOLÓGICO

Files in This Item:
File Description SizeFormat 
ClariceLioba.pdf1.71 MBAdobe PDFThumbnail
View/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.